Wonkam A, Esoh K, Levine R, Ngo Bitoungui V, Mnika K, Nimmagadda N
Nat Commun. 2025; 16(1):2092.
PMID: 40025045
PMC: 11873275.
DOI: 10.1038/s41467-025-57413-5.
Ginete C, Delgadinho M, Santos B, Pinto V, Silva C, Miranda A
Int J Mol Sci. 2023; 24(10).
PMID: 37240136
PMC: 10218819.
DOI: 10.3390/ijms24108792.
Esposito A, Cotta Filho C, Lacchini R
Genet Mol Biol. 2022; 45(3 Suppl 1):e20220157.
PMID: 36264109
PMC: 9583294.
DOI: 10.1590/1678-4685-GMB-2022-0157.
Delgadinho M, Ginete C, Santos B, Fernandes C, Silva C, Miranda A
Int J Mol Sci. 2022; 23(16).
PMID: 36012325
PMC: 9409137.
DOI: 10.3390/ijms23169061.
Pandey A, Estepp J, Raja R, Guolian Kang , Ramkrishna D
Pharmaceutics. 2022; 14(5).
PMID: 35631651
PMC: 9144420.
DOI: 10.3390/pharmaceutics14051065.
Do Genetic Polymorphisms Affect Fetal Hemoglobin (HbF) Levels in Patients With Sickle Cell Anemia Treated With Hydroxyurea? A Systematic Review and Pathway Analysis.
Sales R, Nogueira B, Goncalves Tosatti J, Gomes K, Luizon M
Front Pharmacol. 2022; 12:779497.
PMID: 35126118
PMC: 8814522.
DOI: 10.3389/fphar.2021.779497.
Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.
Patrinos G, Chui D, Hardison R, Steinberg M
Expert Rev Hematol. 2021; 14(10):883-885.
PMID: 34490838
PMC: 9306350.
DOI: 10.1080/17474086.2021.1977117.
Genome-based therapeutic interventions for β-type hemoglobinopathies.
Karamperis K, Tsoumpeli M, Kounelis F, Koromina M, Mitropoulou C, Moutinho C
Hum Genomics. 2021; 15(1):32.
PMID: 34090531
PMC: 8178887.
DOI: 10.1186/s40246-021-00329-0.
Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.
Oliveira-Paula G, Coeli-Lacchini F, Ferezin L, Ferreira G, Pinheiro L, Paula-Garcia W
Eur J Clin Pharmacol. 2021; 77(6):869-877.
PMID: 33410970
DOI: 10.1007/s00228-020-03059-9.
Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening.
Breveglieri G, Pacifico S, Zuccato C, Cosenza L, Sultan S, DAversa E
Int J Mol Sci. 2020; 21(19).
PMID: 33050052
PMC: 7582302.
DOI: 10.3390/ijms21197426.
Sickle Cell Anemia: Variants in the , , and Genes Are Associated With Improved Hydroxyurea Response.
Yahouedehou S, Dos Santos Neres J, da Guarda C, Carvalho S, Santiago R, Figueiredo C
Front Pharmacol. 2020; 11:553064.
PMID: 33013391
PMC: 7510454.
DOI: 10.3389/fphar.2020.553064.
Sickle Cell Disease: Advances in Treatment.
Gardner R
Ochsner J. 2018; 18(4):377-389.
PMID: 30559624
PMC: 6292457.
DOI: 10.31486/toj.18.0076.
Serum of sickle cell disease patients contains fetal hemoglobin silencing factors secreted from leukocytes.
Ikuta T, Sellak H, Liu S, Odo N
J Blood Med. 2018; 9:95-104.
PMID: 29950916
PMC: 6018840.
DOI: 10.2147/JBM.S156999.
Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters.
Yahouedehou S, Carvalho M, Oliveira R, Santiago R, da Guarda C, Carvalho S
Dis Markers. 2018; 2018:6105691.
PMID: 29619129
PMC: 5829363.
DOI: 10.1155/2018/6105691.
Pharmacogenomics of sickle cell disease: steps toward personalized medicine.
Husain M, Hartman A, Desai P
Pharmgenomics Pers Med. 2017; 10:261-265.
PMID: 29089781
PMC: 5656342.
DOI: 10.2147/PGPM.S123427.
Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.
Chondrou V, Kolovos P, Sgourou A, Kourakli A, Pavlidaki A, Kastrinou V
Hum Genomics. 2017; 11(1):24.
PMID: 29061162
PMC: 5654038.
DOI: 10.1186/s40246-017-0120-8.
Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Zhu X, Hu T, Ho M, Wang Y, Yu M, Patel N
Haematologica. 2017; 102(12):1995-2004.
PMID: 28971909
PMC: 5709098.
DOI: 10.3324/haematol.2017.175646.
Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil.
Lacchini R, Muniz J, Nobre Y, Cologna A, Martins A, Tanus-Santos J
Pharmacogenomics J. 2017; 18(2):238-244.
PMID: 28374859
DOI: 10.1038/tpj.2017.2.
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.
Mnika K, Pule G, Dandara C, Wonkam A
OMICS. 2016; 20(10):565-574.
PMID: 27636225
PMC: 5067801.
DOI: 10.1089/omi.2016.0105.
Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience.
Papadopoulou E, Teli A, Theodoridou S, Gompakis N, Economou M
Hippokratia. 2016; 19(2):172-5.
PMID: 27418768
PMC: 4938110.